Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.
Earnings for Chugai Pharmaceutical Co., Ltd. (4519.T)
Earnings in 2023 (TTM): $2.87 B
According to Chugai Pharmaceutical Co., Ltd.'s latest financial reports the company's current earnings (TTM) are $2.87 B. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Chugai Pharmaceutical Co., Ltd.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $2.87 B | $2.1 B |
| 2022 | $3.43 B | $2.42 B |
| 2021 | $2.71 B | $1.96 B |
| 2020 | $1.93 B | $1.39 B |
| 2019 | $1.34 B | $1.02 B |
| 2018 | $784.44 M | $597.38 M |
| 2017 | $626.73 M | $469.66 M |
| 2016 | $480.86 M | $346.15 M |
| 2015 | $563.72 M | $394.81 M |
| 2014 | $491.95 M | $329.28 M |
| 2013 | $496.98 M | $328.73 M |
| 2012 | $486.5 M | $311.36 M |
| 2011 | $369.01 M | $227.58 M |
| 2010 | $424.27 M | $267.62 M |
| 2009 | $577.54 M | $365.8 M |
| 2008 | $407.6 M | $253.61 M |
| 2007 | $429.05 M | $258.75 M |
| 2006 | $406.64 M | $248.14 M |
| 2005 | $556.63 M | $346.41 M |
| 2004 | $371.32 M | $220.36 M |
| 2003 | $318.06 M | $183.73 M |